Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer : a single NZ centre experience
Vyas, Madhusudan; Fagan, J.; Lim, R.; Garett, N.
View fulltext online
Citation:Vyas, M., Fagan, J., Lim, R., & Garett, N. (2020, October). Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer: A single NZ centre experience. Paper presented at the New Zealand Society for Oncology-2020, Auckland, New Zealand.
Permanent link to Research Bank record:https://hdl.handle.net/10652/5028
Objectives Metastatic Castration resistant prostate cancer (mCRPC) Metastatic Castration resistant prostate cancer (mCRPC) and PSMA Various PSMA ligands and radionuclidessuitable for labelling Lu177-PSMA and Mechanism of therapy First reported outcome for Lu177-PSMA-617 Inclusion criteria Exclusion criteria Treatment protocol Response criterion Results: Patient Characteristics Results: Therapy outcomes PSA Response Haematoxicity Quality of Life Outcomes Feedback from patients Image evaluation for therapy responses Limitations Future plan Conclusion References